• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

    4.360 +0.360 (+9.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Foghorn Therapeutics Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
     
    Via Benzinga
    Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    These stocks are gapping in today's session
    Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
    Via Chartmill
    Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
    Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT 
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
     
    Via Benzinga
    Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday
     
    Via Benzinga
    Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
     
    Via Benzinga
    This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
     
    Via Benzinga
    Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
     
    Via Benzinga
    Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
    Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. 
    Via Benzinga
    Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in the BMO Oncology Summit
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.